| Literature DB >> 29437554 |
Francesca Pellicano1, Laura Park1, Lisa E M Hopcroft1, Mansi M Shah1, Lorna Jackson1, Mary T Scott1, Cassie J Clarke1, Amy Sinclair1, Sheela A Abraham1, Alan Hair1, G Vignir Helgason1, Mark Aspinall-O'Dea2, Ravi Bhatia3, Gustavo Leone4, Kamil R Kranc5, Anthony D Whetton2, Tessa L Holyoake1.
Abstract
Chronic myeloid leukemia (CML) stem/progenitor cells (SPCs) express a transcriptional program characteristic of proliferation, yet can achieve and maintain quiescence. Understanding the mechanisms by which leukemic SPCs maintain quiescence will help to clarify how they persist during long-term targeted treatment. We have identified a novel BCR-ABL1 protein kinase-dependent pathway mediated by the upregulation of hsa-mir183, the downregulation of its direct target early growth response 1 (EGR1), and, as a consequence, upregulation of E2F1. We show here that inhibition of hsa-mir183 reduced proliferation and impaired colony formation of CML SPCs. Downstream of this, inhibition of E2F1 also reduced proliferation of CML SPCs, leading to p53-mediated apoptosis. In addition, we demonstrate that E2F1 plays a pivotal role in regulating CML SPC proliferation status. Thus, for the first time, we highlight the mechanism of hsa-mir183/EGR1-mediated E2F1 regulation and demonstrate this axis as a novel, critical factor for CML SPC survival, offering new insights into leukemic stem cell eradication.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29437554 PMCID: PMC6027092 DOI: 10.1182/blood-2017-05-783845
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113